Symbol="XBIO"
AssetType="Common Stock"
Name="Xenetic Biosciences Inc"
Description="Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts."
CIK="1534525"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="40 SPEEN STREET, SUITE 102, FRAMINGHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="6276800"
EBITDA="-5746008"
PERatio="None"
PEGRatio="0"
BookValue="8.48"
DividendPerShare="0"
DividendYield="0"
EPS="-4.37"
RevenuePerShareTTM="1.313"
ProfitMargin="0"
OperatingMarginTTM="-3.126"
ReturnOnAssetsTTM="-0.237"
ReturnOnEquityTTM="-0.391"
RevenueTTM="1923800"
GrossProfitTTM="1160700"
DilutedEPSTTM="-4.37"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.557"
AnalystTargetPrice="40"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.615"
PriceToBookRatio="0.433"
EVToRevenue="0.117"
EVToEBITDA="1.08"
Beta="2.873"
num_52WeekHigh="9.94"
num_52WeekLow="2.401"
num_50DayMovingAverage="3.368"
num_200DayMovingAverage="4.259"
SharesOutstanding="1516700"
DividendDate="2019-06-25"
ExDividendDate="None"
symbol="XBIO"
open="4.07"
high="4.33"
low="3.73"
price="3.85"
volume="25962.00"
latest_trading_day="2023-07-27"
previous_close="4.14"
change="-0.29"
change_percent="-6.9734%"
aroon_positive_momentum_days="33"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="33"
Volume_recent_avg="43174"
Change_recent_avg="0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.54"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="33"
Aroon_momentum_negative="67"
image_negative_thumbnail_id_1="132"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0044.jpeg"
image_negative_thumbnail_id_2="167"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0009.jpeg"
image_neutral_thumbnail_id_1="579"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0020.jpeg"
image_neutral_thumbnail_id_2="568"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_positive_thumbnail_id_1="632"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0076.jpeg"
image_positive_thumbnail_id_2="1015"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0177.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
